Lipids in innate antiviral defense

Cell Host and Microbe

Volumn 14, Issue 4, 2013, Pages 379-385

  Schoggins, John W ^a   Randall, Glenn ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYCHOLESTEROL; ANTIVIRUS AGENT; CHOLESTEROL; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; INTERFERON; INTERFERON INDUCIBLE TRANSMEMBRANE PROTEIN 1; INTERFERON INDUCIBLE TRANSMEMBRANE PROTEIN 2; INTERFERON INDUCIBLE TRANSMEMBRANE PROTEIN 3; LIPID; LOW DENSITY LIPOPROTEIN RELATED RECEPTOR 1; MEMBRANE PROTEIN; MEVALONIC ACID; OMEGA 3 FATTY ACID LIPID MEDIATOR 1; SIMVASTATIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; B LYMPHOCYTE; CYTOMEGALOVIRUS; INFLUENZA A; INNATE IMMUNITY; LIPID COMPOSITION; MACROPHAGE; MEMBRANE FLUIDITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PRENYLATION; REVIEW; STEROL SYNTHESIS; VESICULAR STOMATITIS VIRUS; VIRION;

ANIMALS; HUMANS; IMMUNITY, INNATE; MEMBRANE LIPIDS; VIRUS DISEASES; VIRUS INTERNALIZATION; VIRUSES;

EID: 84886071901     PISSN: 19313128     EISSN: 19346069     Source Type: Journal    
DOI: 10.1016/j.chom.2013.09.010     Document Type: Review

References (49)

1. A. Ablasser, and V. Hornung DNA sensing unchained Cell Res. 23 2013 585 587
2. S. Amini-Bavil-Olyaee, Y.J. Choi, J.H. Lee, M. Shi, I.C. Huang, M. Farzan, and J.U. Jung The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry Cell Host Microbe 13 2013 452 464
3. C.C. Bailey, I.C. Huang, C. Kam, and M. Farzan Ifitm3 limits the severity of acute influenza in mice PLoS Pathog. 8 2012 e1002909
4. D.R. Bauman, A.D. Bitmansour, J.G. McDonald, B.M. Thompson, G. Liang, and D.W. Russell 25-Hydroxycholesterol secreted by macrophages in response to Toll-like receptor activation suppresses immunoglobulin A production Proc. Natl. Acad. Sci. USA 106 2009 16764 16769
5. M. Blanc, W.Y. Hsieh, K.A. Robertson, S. Watterson, G. Shui, P. Lacaze, M. Khondoker, P. Dickinson, G. Sing, and S. Rodríguez-Martín Host defense against viral infection involves interferon mediated down-regulation of sterol biosynthesis PLoS Biol. 9 2011 e1000598
6. M. Blanc, W.Y. Hsieh, K.A. Robertson, K.A. Kropp, T. Forster, G. Shui, P. Lacaze, S. Watterson, S.J. Griffiths, and N.J. Spann The transcription factor STAT-1 couples macrophage synthesis of 25-hydroxycholesterol to the interferon antiviral response Immunity 38 2013 106 118
7. A.L. Brass, I.C. Huang, Y. Benita, S.P. John, M.N. Krishnan, E.M. Feeley, B.J. Ryan, J.L. Weyer, L. van der Weyden, and E. Fikrig The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus Cell 139 2009 1243 1254
8. J. Chevallier, Z. Chamoun, G. Jiang, G. Prestwich, N. Sakai, S. Matile, R.G. Parton, and J. Gruenberg Lysobisphosphatidic acid controls endosomal cholesterol levels J. Biol. Chem. 283 2008 27871 27880
9. V. Chukkapalli, N.S. Heaton, and G. Randall Lipids at the interface of virus-host interactions Curr. Opin. Microbiol. 15 2012 512 518
10. M.S. Diamond, and M. Farzan The broad-spectrum antiviral functions of IFIT and IFITM proteins Nat. Rev. Immunol. 13 2013 46 57
11. J. Ecker, G. Liebisch, M. Englmaier, M. Grandl, H. Robenek, and G. Schmitz Induction of fatty acid synthesis is a key requirement for phagocytic differentiation of human monocytes Proc. Natl. Acad. Sci. USA 107 2010 7817 7822
12. A.R. Everitt, S. Clare, T. Pertel, S.P. John, R.S. Wash, S.E. Smith, C.R. Chin, E.M. Feeley, J.S. Sims, D.J. Adams GenISIS Investigators MOSAIC Investigators IFITM3 restricts the morbidity and mortality associated with influenza Nature 484 2012 519 523
13. E.M. Feeley, J.S. Sims, S.P. John, C.R. Chin, T. Pertel, L.M. Chen, G.D. Gaiha, B.J. Ryan, R.O. Donis, S.J. Elledge, and A.L. Brass IFITM3 inhibits influenza A virus infection by preventing cytosolic entry PLoS Pathog. 7 2011 e1002337
14. D.N. Fusco, C. Brisac, S.P. John, Y.W. Huang, C.R. Chin, T. Xie, H. Zhao, N. Jilg, L. Zhang, and S. Chevaliez A genetic screen identifies interferon-α effector genes required to suppress hepatitis C virus replication Gastroenterology 144 2013 1438 1449 e1-e9
15. N. Gudleski-O'Regan, T.M. Greco, I.M. Cristea, and T. Shenk Increased expression of LDL receptor-related protein 1 during human cytomegalovirus infection reduces virion cholesterol and infectivity Cell Host Microbe 12 2012 86 96
16. N.S. Heaton, and G. Randall Multifaceted roles for lipids in viral infection Trends Microbiol. 19 2011 368 375
17. I.C. Huang, C.C. Bailey, J.L. Weyer, S.R. Radoshitzky, M.M. Becker, J.J. Chiang, A.L. Brass, A.A. Ahmed, X. Chi, and L. Dong Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus PLoS Pathog. 7 2011 e1001258
18. S.P. John, C.R. Chin, J.M. Perreira, E.M. Feeley, A.M. Aker, G. Savidis, S.E. Smith, A.E. Elia, A.R. Everitt, and M. Vora The CD225 domain of IFITM3 is required for both IFITM protein association and inhibition of influenza A virus and dengue virus replication J. Virol. 87 2013 7837 7852
19. S. Karki, M.M. Li, J.W. Schoggins, S. Tian, C.M. Rice, and M.R. MacDonald Multiple interferon stimulated genes synergize with the zinc finger antiviral protein to mediate anti-alphavirus activity PLoS ONE 7 2012 e37398
20. K. Li, R.M. Markosyan, Y.M. Zheng, O. Golfetto, B. Bungart, M. Li, S. Ding, Y. He, C. Liang, and J.C. Lee IFITM proteins restrict viral membrane hemifusion PLoS Pathog. 9 2013 e1003124
21. S.Y. Liu, D.J. Sanchez, R. Aliyari, S. Lu, and G. Cheng Systematic identification of type I and type II interferon-induced antiviral factors Proc. Natl. Acad. Sci. USA 109 2012 4239 4244
22. S.Y. Liu, R. Aliyari, K. Chikere, G. Li, M.D. Marsden, J.K. Smith, O. Pernet, H. Guo, R. Nusbaum, and J.A. Zack Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol Immunity 38 2013 92 105
23. J. Lu, Q. Pan, L. Rong, W. He, S.L. Liu, and C. Liang The IFITM proteins inhibit HIV-1 infection J. Virol. 85 2011 2126 2137
24. J. Lucifora, K. Esser, and U. Protzer Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes Antiviral Res. 97 2013 195 197
25. P. Metz, E. Dazert, A. Ruggieri, J. Mazur, L. Kaderali, A. Kaul, U. Zeuge, M.P. Windisch, M. Trippler, and V. Lohmann Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication Hepatology 56 2012 2082 2093
26. M. Morita, K. Kuba, A. Ichikawa, M. Nakayama, J. Katahira, R. Iwamoto, T. Watanebe, S. Sakabe, T. Daidoji, and S. Nakamura The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza Cell 153 2013 112 125
27. T.S. Moser, D. Schieffer, and S. Cherry AMP-activated kinase restricts Rift Valley fever virus infection by inhibiting fatty acid synthesis PLoS Pathog. 8 2012 e1002661
28. K. Park, and A.L. Scott Cholesterol 25-hydroxylase production by dendritic cells and macrophages is regulated by type I interferons J. Leukoc. Biol. 88 2010 1081 1087
29. J.P. Pezacki, S.M. Sagan, A.M. Tonary, Y. Rouleau, S. Bélanger, L. Supekova, and A.I. Su Transcriptional profiling of the effects of 25-hydroxycholesterol on human hepatocyte metabolism and the antiviral state it conveys against the hepatitis C virus BMC Chem. Biol. 9 2009 2
30. R.K. Plemper Cell entry of enveloped viruses Curr Opin Virol 1 2011 92 100
31. S. Rasheed, J.S. Yan, A. Lau, and A.S. Chan HIV replication enhances production of free fatty acids, low density lipoproteins and many key proteins involved in lipid metabolism: a proteomics study PLoS ONE 3 2008 e3003
32. A.J. Sadler, and B.R. Williams Interferon-inducible antiviral effectors Nat. Rev. Immunol. 8 2008 559 568
33. B. Sainz Jr., N. Barretto, D.N. Martin, N. Hiraga, M. Imamura, S. Hussain, K.A. Marsh, X. Yu, K. Chayama, W.A. Alrefai, and S.L. Uprichard Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor Nat. Med. 18 2012 281 285
34. C.E. Samuel Antiviral actions of interferons Clin. Microbiol. Rev. 14 2001 778 809
35. J.W. Schoggins, S.J. Wilson, M. Panis, M.Y. Murphy, C.T. Jones, P. Bieniasz, and C.M. Rice A diverse range of gene products are effectors of the type I interferon antiviral response Nature 472 2011 481 485
36. J.Y. Seo, R. Yaneva, and P. Cresswell Viperin: a multifunctional, interferon-inducible protein that regulates virus replication Cell Host Microbe 10 2011 534 539
37. D.A. Sheridan, R.D. Neely, and M.F. Bassendine Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs) Clin Res Hepatol Gastroenterol 37 2013 10 16
38. M.R. St Vincent, C.C. Colpitts, A.V. Ustinov, M. Muqadas, M.A. Joyce, N.L. Barsby, R.F. Epand, R.M. Epand, S.A. Khramyshev, and O.A. Valueva Rigid amphipathic fusion inhibitors, small molecule antiviral compounds against enveloped viruses Proc. Natl. Acad. Sci. USA 107 2010 17339 17344
39. J. Stebbing, B. Gazzard, L. Kim, S. Portsmouth, A. Wildfire, I. Teo, M. Nelson, M. Bower, F. Gotch, and S. Shaunak The heat-shock protein receptor CD91 is up-regulated in monocytes of HIV-1-infected "true" long-term nonprogressors Blood 101 2003 4000 4004
40. V.C. Tam, O. Quehenberger, C.M. Oshansky, R. Suen, A.M. Armando, P.M. Treuting, P.G. Thomas, E.A. Dennis, and A. Aderem Lipidomic profiling of influenza infection identifies mediators that induce and resolve inflammation Cell 154 2013 213 227
41. E. Teissier, and E.I. Pécheur Lipids as modulators of membrane fusion mediated by viral fusion proteins Eur. Biophys. J. 36 2007 887 899
42. E. Teissier, G. Zandomeneghi, A. Loquet, D. Lavillette, J.P. Lavergne, R. Montserret, F.L. Cosset, A. Böckmann, B.H. Meier, F. Penin, and E.I. Pécheur Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol PLoS ONE 6 2011 e15874
43. F. Vigant, J. Lee, A. Hollmann, L.B. Tanner, Z. Akyol Ataman, T. Yun, G. Shui, H.C. Aguilar, D. Zhang, and D. Meriwether A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion PLoS Pathog. 9 2013 e1003297
44. E.E. Walsh Statins and influenza: can we move forward? J. Infect. Dis. 205 2012 1 3
45. C. Wilkins, J. Woodward, D.T. Lau, A. Barnes, M. Joyce, N. McFarlane, J.A. McKeating, D.L. Tyrrell, and M. Gale Jr. IFITM1 is a tight junction protein that inhibits hepatitis C virus entry Hepatology 57 2013 461 469
46. M.C. Wolf, A.N. Freiberg, T. Zhang, Z. Akyol-Ataman, A. Grock, P.W. Hong, J. Li, N.F. Watson, A.Q. Fang, and H.C. Aguilar A broad-spectrum antiviral targeting entry of enveloped viruses Proc. Natl. Acad. Sci. USA 107 2010 3157 3162
47. J.S. Yount, R.A. Karssemeijer, and H.C. Hang S-palmitoylation and ubiquitination differentially regulate interferon-induced transmembrane protein 3 (IFITM3)-mediated resistance to influenza virus J. Biol. Chem. 287 2012 19631 19641
48. M. Zasloff, A.P. Adams, B. Beckerman, A. Campbell, Z. Han, E. Luijten, I. Meza, J. Julander, A. Mishra, and W. Qu Squalamine as a broad-spectrum systemic antiviral agent with therapeutic potential Proc. Natl. Acad. Sci. USA 108 2011 15978 15983
49. H. Zhao, W. Lin, K. Kumthip, D. Cheng, D.N. Fusco, O. Hofmann, N. Jilg, A.W. Tai, K. Goto, and L. Zhang A functional genomic screen reveals novel host genes that mediate interferon-alpha's effects against hepatitis C virus J. Hepatol. 56 2012 326 333